Skip to main content
Log in

Novel glycosaminoglycan precursors as anti-amyloid agents, Part III

  • Alzheimer’s Therapeutics: Anti-Amyloid
  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

In vivo amyloids consist of two classes of constituents. The first is the disease-defining protein, e.g., amyloid β (Aβ) in Alzheimer’s disease (AD). The second is a set of common structural components that usually are the building blocks of basement membrane (BM), a tissue structure that serves as a scaffold onto which cells normally adhere. In vitro binding interactions between one of these BM components and amyloidogenic proteins rapidly change the conformation of the amyloidogenic protein into amyloid fibrils. The offending BM component is a heparan sulfate (HS) proteoglycan (HSPG), part of which is protein, and the remainder is a specific linear polysaccharide that is the portion responsible for binding and imparting the typical amyloid structure to the amyloid precursor protein/peptide. Our past work has demonstrated that agents that inhibit the binding between HS and the amyloid precursor are effective antiamyloid compounds both in vitro and in vivo. Similarly, 4-deoxy analogs of glucosamine (a precursor of HS biosynthesis) are effective antiamyloid compounds both in culture and in vivo. Our continuing work concerns (1) the testing of our 4-deoxy compounds in a mouse transgenic model of AD, and (2) the continuing design and synthesis of modified sugar precursors of HS, which when incorporated into the polysaccharide will alter its structure so that it loses its amyloid-inducing properties. Since our previous report, 14 additional compounds have been designed and synthesized based on the known steps involved in HS biosynthesis. Of these, eight have been assessed for their effect on HS biosynthesis in hepatocyte tissue cultures, and the two anomers of a 4-deoxy-d-glucosamine analog have been assessed for their inflammation-associated amyloid (AA amyloid) inhibitory properties in vivo. The promising in vivo results with these two compounds have prompted studies using a murine transgenic model of brain Aβ amyloidogenesis. A macrophage tissue-culture model of AA amyloidogenesis has been devised based on the work of Kluve-Beckerman et al. and modified so as to assess compounds in the absence of potential in vivo confounding variables. Preliminary results indicate that the anomers of interest also inhibit AA amyloid deposition in macrophage tissue culture. Finally, an in vitro technique, using liver Golgi (the site of HS synthesis) rather than whole cells, has been devised to directly assess the effect of analogs on HS biosynthesis. The majority of the novel sugars prepared to date are analogs of N-acetylglucosamine. They have been modified either at the 2-N, C-3, C-4, or C-3 and C-4 positions. Results with the majority of the 2-N analogs suggest that hepacyte N-demethylases remove the N-substituent removal. Several of these have the desired effect on HS biosynthesis using hepatocyte cultures and will be assessed in the culture and in vivo AA amyloid models. To date 3-deoxy and 3,4-dideoxy analogs have failed to affect HS synthesis significantly. Compounds incorporating the 6-deoxy structural feature are currently being designed and synthesized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Berkin A., Szarek M. A., Plenkiewicz J., Szarek W. A., and Kisilevsky R. (2000a) Synthesis of 4-deoxy analogues of 2-acetamido-2-deoxy-D-glucose and 2-acetamido-2-deoxy-D-xylose and their effects of glycoconjugate biosynthesis. Carbohydr. Res. 325, 30–45.

    Article  PubMed  CAS  Google Scholar 

  • Berkin A., Szarek W. A., and Kisilevsky R. (2000b) Synthesis of 4-deoxy-4-fluoro analogues of 2-acetamido-2-deoxy-D-glucose and 2-acetamido-2-deoxy-D-galactose and their effects on cellular glycosaminoglycan biosynthesis. Carbohydr. Res. 326, 250–263.

    Article  PubMed  CAS  Google Scholar 

  • Castillo G. M., Cummings J. A., Yang W. H., Judge M. E., Sheardown M. E., Sheardown M. J., Rimvall K., et al. (1998) Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan’s enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47, 612–620.

    Article  PubMed  CAS  Google Scholar 

  • Kisilevsky R. and Fraser P. E. (1997) Aβ amyloidogenesis: unique or variation on a systemic theme? Crit. Rev. Biochem. Mol. Biol. 32, 361–404.

    PubMed  CAS  Google Scholar 

  • Kisilevsky R., Lemieux L. J., Fraser P. E., Kong X.-Q., Hultin P. G., and Szarek W. A. (1995) Arresting amyloidosis in vivo using small-molecular anionic sulphonates or sulphates: implications for Alzheimer’s disease. Nat. Med. 1, 143–148.

    Article  PubMed  CAS  Google Scholar 

  • Kisilevsky R. and Szarek W. A. (2002a) Novel glycosaminoglycan precursors as anti-amyloid agents, in Drug Discovery and Development for Alzheimer’s Disease 2000, Fillit H. M. and O’Connell A. W., eds., Springer, New York, pp. 98–105.

    Google Scholar 

  • Kisilevsky R. and Szarek W. A. (2002b) Novel glycosaminoglycan precursors as anti-amyloid agents, Part II. J. Mol. Neurosci. 19, 45–50.

    Article  PubMed  CAS  Google Scholar 

  • Kluve-Beckerman B., Liepnieks J. J., Wang L. S., and Benson M. D. (1999) A cell culture system for the study of amyloid pathogenesis—amyloid formation by peritoneal macrophages cultures with recombinant serum amyloid A. Am. J. Pathol. 155, 123–133.

    PubMed  CAS  Google Scholar 

  • Lindahl B., Eriksson L., and Lindahl U. (1995) Structure of heparan sulphate from human brain, with special regard to Alzheimer’s disease. Biochem. J. 306, 177–184.

    PubMed  CAS  Google Scholar 

  • Lindahl B., Eriksson L., Spillman D., Caterson B., and Lindahl U. (1996) Selective loss of cerebral keratan sulfate in Alzheimer’s disease. Biochem. J. 306, 177–184.

    Google Scholar 

  • Lindahl B. and Lindahl U. (1997) Amyloid-specific heparan sulfate from human liver and spleen. J. Biol. Chem. 272, 26,091–26,094.

    Article  CAS  Google Scholar 

  • Lindahl B., Westling C., Gimenez-Gallego G., Lindahl U., and Salmivirta M. (1999) Common binding sites for β-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J. Biol. Chem. 274, 30,631–30,635.

    Article  CAS  Google Scholar 

  • Lindahl U., Kushke M., Lindholt K., and Oscarsson L. G. (1989) Biosynthesis of heparin and heparan sulfate. Ann. N. Y. Acad. Sci. 556, 36–50.

    Article  PubMed  CAS  Google Scholar 

  • McCubbin W. D., Kay C. M., Narindrasorasak S., and Kisilevsky R. (1988) Circular dichroism and fluorescence studies on two murine serum amyloid A proteins. Biochem. J. 256, 775–783.

    PubMed  CAS  Google Scholar 

  • Mclaurin J., Franklin T, Kuhns W. J., and Fraser P. E. (1999a) A sulfated proteoglycan aggregation factor mediates amyloid-β peptide fibril formation and neurotoxicity. Amyloid 6, 233–243.

    PubMed  CAS  Google Scholar 

  • Mclaurin J., Franklin T., Zhang X. Q., Deng J. P., and Fraser P. E. (1999b) Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans—effects on fibril nucleation and growth. Eur. J. Biochem. 266, 1101–1110.

    Article  PubMed  CAS  Google Scholar 

  • Subrahmanyan L. and Kisilevsky R. (1988) Effects of culture substrates and normal hepatic sinusoidal cells on in-vitro hepatocyte synthesis of apo-SAA. Scand. J. Immunol. 27, 251–260.

    Article  PubMed  CAS  Google Scholar 

  • Thomas S. S., Plenkiewicz J., Ison E. R., Bols M., Zou W., Szarek W. A., and Kisilevsky R. (1995) Influence of monosaccharide derivatives on liver cell glycosaminoglycan synthesis: 3-deoxy-D-xylo-hexose (2-deoxy-D-galactose) and methyl (methyl 4-chloro-4-deoxy-β-D-galactopyranosid)uronate. Biochim. Biophys. Acta 1272, 37–48.

    PubMed  Google Scholar 

  • Westermark P. (1997) Classification of amyloid fibril proteins and their precursors: an ongoing discussion. Amyloid 4, 216–218.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert Kisilevsky.

Additional information

For Part I, see Kisilevsky and Szarek (2002a). For Part II, see Kisilevsky and Szarek (2002b).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kisilevsky, R., Szarek, W.A., Ancsin, J. et al. Novel glycosaminoglycan precursors as anti-amyloid agents, Part III. J Mol Neurosci 20, 291–297 (2003). https://doi.org/10.1385/JMN:20:3:291

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/JMN:20:3:291

Index Entries

Navigation